Ocrevus in Advanced Progressive Multiple Sclerosis (pertaining to younger and elder patients with MS)
a video by : Dr. Brandon Beaber Does ocrevus work in people with progressive MS with more significant disability? The…
Stopping Ocrevus in stable MS doesn’t seem to raise 2-year risk, study finds
But patients should restart treatment after 2.5 years or disease activity Written by Marisa Wexler, MS | March 17, 2026 For people with multiple…
Stuart Schlossman
Ocrevus and Tysabri appear to work equally well to control relapsing MS
Danish study finds no difference in relapse rates or disease progression Written by Margarida Maia, PhD | February 26, 2026 Ocrevus and Tysabri…
Stuart Schlossman
ECTRIMS 2025: Medical director at Genentech discusses potential of Ocrevus as a pediatric MS treatment
Click above image to listen David Jones, MD, principal medical director of multiple sclerosis at Genentech, highlights how pediatric MS…
Stuart Schlossman
Two-Year CHIMES Study Data Highlight Effect of Ocrelizumab in Diverse Relapsing MS Patient Population
Key Takeaways New findings reveal ocrelizumab significantly improves symptoms, cognition, and fatigue in Black and Hispanic patients with relapsing multiple…
Stuart Schlossman
Genentech Provides Update on Phase III Ocrevus High Dose Study in People With Relapsing Multiple Sclerosis
MUSETTE trial was designed to determine whether a higher dose of the currently approved Ocrevus IV 600 mg would provide…
Stuart Schlossman
Genentech Provides Update on Phase III Ocrevus High Dose Study in People With Relapsing Multiple Sclerosis
– MUSETTE trial was designed to determine whether a higher dose of the currently approved Ocrevus IV 600 mg would provide…
Stuart Schlossman
Press Release: FDA Approves Ocrevus Zunovo™ as the First and Only Twice-a-Year 10-Minute Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis
Ocrevus Zunovo™ has the potential to expand treatment options to centers without IV infrastructure or with IV constraints, like at a…
Stuart Schlossman
New Data Shows Positive Efficacy and Safety Outcomes After 10 Years of Ocrevus Treatment
October 18, 2023 Rosanna Sutherby, Pharm.D. In 2017, the FDA approved Genentech’s Ocrevus (ocrelizumab) for the treatment of relapsing forms…
Stuart Schlossman
First-Ever Clinical Trial Exclusively in Black and Hispanic / Latinx People Living With Multiple Sclerosis Shows Genentech’s Ocrevus Effectively Manages Disease Activity
October 10, 2023 Black and Hispanic / Latinx people with multiple sclerosis (MS) often experience more severe disease and greater…
Stuart Schlossman
